Cargando…
Role of Matrix Metalloproteinase Activity in the Neurovascular Protective Effects of Angiotensin Antagonism
Background and Purpose. Oxidative stress and matrix metalloproteinase (MMP) activity have been identified as key mediators of early vascular damage after ischemic stroke. Somewhat surprisingly, the angiotensin II type 1 receptor (AT1) blocker, candesartan, has been shown to acutely increase MMP acti...
Autores principales: | , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Hindawi Publishing Corporation
2014
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4134816/ https://www.ncbi.nlm.nih.gov/pubmed/25147751 http://dx.doi.org/10.1155/2014/560491 |
_version_ | 1782330915596271616 |
---|---|
author | Ishrat, Tauheed Kozak, Anna Alhusban, Ahmed Pillai, Bindu Johnson, Maribeth H. El-Remessy, Azza B. Ergul, Adviye Fagan, Susan C. |
author_facet | Ishrat, Tauheed Kozak, Anna Alhusban, Ahmed Pillai, Bindu Johnson, Maribeth H. El-Remessy, Azza B. Ergul, Adviye Fagan, Susan C. |
author_sort | Ishrat, Tauheed |
collection | PubMed |
description | Background and Purpose. Oxidative stress and matrix metalloproteinase (MMP) activity have been identified as key mediators of early vascular damage after ischemic stroke. Somewhat surprisingly, the angiotensin II type 1 receptor (AT1) blocker, candesartan, has been shown to acutely increase MMP activity while providing neurovascular protection. We aimed to determine the contribution of MMP and nitrative stress to the effects of angiotensin blockade in experimental stroke. Methods. Wistar rats (n = 9–14/group; a total of 99) were treated in a factorial design with candesartan 1 mg/kg IV, alone or in combination with either a peroxynitrite decomposition catalyst, FeTPPs, 30 mg/kg IP or GM6001 50 mg/kg IP (MMP inhibitor). Neurological deficit, infarct, size and hemorrhagic transformation (HT) were measured after 3 h of middle cerebral artery occlusion (MCAO) and 21 h of reperfusion. MMP activity and nitrotyrosine expression were also measured. Results. Candesartan reduced infarct size and HT when administered alone (P = 0.0011) and in combination with FeTPPs (P = 0.0016). GM6001 did not significantly affect HT when administered alone, but the combination with candesartan caused increased HT (P < 0.0001) and worsened neurologic score (P = 0.028). Conclusions. Acute administration of candesartan reduces injury after stroke despite increasing MMP activity, likely by an antioxidant mechanism. |
format | Online Article Text |
id | pubmed-4134816 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2014 |
publisher | Hindawi Publishing Corporation |
record_format | MEDLINE/PubMed |
spelling | pubmed-41348162014-08-21 Role of Matrix Metalloproteinase Activity in the Neurovascular Protective Effects of Angiotensin Antagonism Ishrat, Tauheed Kozak, Anna Alhusban, Ahmed Pillai, Bindu Johnson, Maribeth H. El-Remessy, Azza B. Ergul, Adviye Fagan, Susan C. Stroke Res Treat Research Article Background and Purpose. Oxidative stress and matrix metalloproteinase (MMP) activity have been identified as key mediators of early vascular damage after ischemic stroke. Somewhat surprisingly, the angiotensin II type 1 receptor (AT1) blocker, candesartan, has been shown to acutely increase MMP activity while providing neurovascular protection. We aimed to determine the contribution of MMP and nitrative stress to the effects of angiotensin blockade in experimental stroke. Methods. Wistar rats (n = 9–14/group; a total of 99) were treated in a factorial design with candesartan 1 mg/kg IV, alone or in combination with either a peroxynitrite decomposition catalyst, FeTPPs, 30 mg/kg IP or GM6001 50 mg/kg IP (MMP inhibitor). Neurological deficit, infarct, size and hemorrhagic transformation (HT) were measured after 3 h of middle cerebral artery occlusion (MCAO) and 21 h of reperfusion. MMP activity and nitrotyrosine expression were also measured. Results. Candesartan reduced infarct size and HT when administered alone (P = 0.0011) and in combination with FeTPPs (P = 0.0016). GM6001 did not significantly affect HT when administered alone, but the combination with candesartan caused increased HT (P < 0.0001) and worsened neurologic score (P = 0.028). Conclusions. Acute administration of candesartan reduces injury after stroke despite increasing MMP activity, likely by an antioxidant mechanism. Hindawi Publishing Corporation 2014 2014-07-24 /pmc/articles/PMC4134816/ /pubmed/25147751 http://dx.doi.org/10.1155/2014/560491 Text en Copyright © 2014 Tauheed Ishrat et al. https://creativecommons.org/licenses/by/3.0/ This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Research Article Ishrat, Tauheed Kozak, Anna Alhusban, Ahmed Pillai, Bindu Johnson, Maribeth H. El-Remessy, Azza B. Ergul, Adviye Fagan, Susan C. Role of Matrix Metalloproteinase Activity in the Neurovascular Protective Effects of Angiotensin Antagonism |
title | Role of Matrix Metalloproteinase Activity in the Neurovascular Protective Effects of Angiotensin Antagonism |
title_full | Role of Matrix Metalloproteinase Activity in the Neurovascular Protective Effects of Angiotensin Antagonism |
title_fullStr | Role of Matrix Metalloproteinase Activity in the Neurovascular Protective Effects of Angiotensin Antagonism |
title_full_unstemmed | Role of Matrix Metalloproteinase Activity in the Neurovascular Protective Effects of Angiotensin Antagonism |
title_short | Role of Matrix Metalloproteinase Activity in the Neurovascular Protective Effects of Angiotensin Antagonism |
title_sort | role of matrix metalloproteinase activity in the neurovascular protective effects of angiotensin antagonism |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4134816/ https://www.ncbi.nlm.nih.gov/pubmed/25147751 http://dx.doi.org/10.1155/2014/560491 |
work_keys_str_mv | AT ishrattauheed roleofmatrixmetalloproteinaseactivityintheneurovascularprotectiveeffectsofangiotensinantagonism AT kozakanna roleofmatrixmetalloproteinaseactivityintheneurovascularprotectiveeffectsofangiotensinantagonism AT alhusbanahmed roleofmatrixmetalloproteinaseactivityintheneurovascularprotectiveeffectsofangiotensinantagonism AT pillaibindu roleofmatrixmetalloproteinaseactivityintheneurovascularprotectiveeffectsofangiotensinantagonism AT johnsonmaribethh roleofmatrixmetalloproteinaseactivityintheneurovascularprotectiveeffectsofangiotensinantagonism AT elremessyazzab roleofmatrixmetalloproteinaseactivityintheneurovascularprotectiveeffectsofangiotensinantagonism AT erguladviye roleofmatrixmetalloproteinaseactivityintheneurovascularprotectiveeffectsofangiotensinantagonism AT fagansusanc roleofmatrixmetalloproteinaseactivityintheneurovascularprotectiveeffectsofangiotensinantagonism |